Acasti Pharma Inc.

Acasti Pharma Inc. in its Over-Allotment Option for its Public Offering of Common Shares


Acasti Pharma Inc.


US$11 million


Capital Markets

Date Closed

January 2018



Lead Office


On December 27, 2017, Acasti Pharma Inc. (“Acasti”) completed its underwritten public offering of 9,900,990 common shares together with accompanying warrants to purchase an aggregate of 9,802,935 common shares at a combined price to the public of US$1.01 per share and accompanying warrant, for aggregate gross proceeds to Acasti of approx. US$10 million. The Benchmark Company, LLC and Dawson James Securities, Inc. acted as book-running managers for the offering.

On January 22, 2018, the underwriters exercised their over-allotment option, in part, and Acasti completed an additional issuance of 776,179 common shares for aggregate gross proceeds to Acasti of approximately US$800,000, upon the same terms set forth under the larger offering.

Acasti, headquartered in Laval, Québec, is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. 

Osler, Hoskin & Harcourt LLP represented Acasti Pharma Inc. with a team led by François Paradis that included Jason Comerford, Jeremy Brisset and Jillian Mulroy (Corporate) .